Effect of Intraperitoneal Hyperthermic Perfusion Combined with XELOX Chemotherapy Regimen for the Treatment of Gastric Cancer Ascites
Objective To observe the clinical efficacy of intraperitoneal hyperthermic perfusion of recombinant human endostatin injection(Endeavour)combined with XELOX chemotherapy regimen(oxaliplatin+capecitabine)in the treatment of gastric cancer ascites.Methods To include 48 patients with gastric cancer ascites who were treated with XELOX chemotherapy regimen in hospital from January 2020 to December 2021 in the control group,and 48 patients with gastric cancer ascites who were treated with intraperitoneal hyperthermic perfusion combined with XELOX chemotherapy regimen in hospitals from January 2022 to December 2022 were included in the observation group.The efficacy and quality of life of two groups of patients[evaluated using the Karnofsky performance scale(KPS)]were compared.The patient's immune function[T lymphocyte subpopulations(CD3+,CD4+,CD4+/CD8+)]before treatment and during the four cycles of treatment were compared.The occurrence of adverse reaction during treatment were counted.Results After 4 cycles of treatment,the overall efficacy of the observation group was better than that of the control group,and the total effective rate of treatment was higher than that of the control group(P＜0.05).After 4 treatment cycles,the improvement rate of quality of life in the observation group was higher than that in the control group(P＜0.05).After 4 cycles of treatment,the levels of CD3+,CD4+,CD4+/CD8+in both groups decreased compared to before treatment,but the levels of all indicators in the observation group were higher than those in the control group(P＜0.05).During the treatment period,there was no statistical difference in the incidence of toxic side effects between the two groups(P＞0.05).Conclusion On the basis of XELOX chemotherapy regimen,the addition of intraperitoneal hyperthermic perfusion with Endeavour for the treatment of gastric cancer ascites has a good therapeutic effect,which can improve the patient's quality of life,reduce immune suppression caused by chemotherapy drug use,and do not increase the risk of toxic side effects.
gastric cancermalignant peritoneal effusionchemotherapyintraperitoneal hyperthermic perfusionrecombinant human endostatinquality of life
NETL
NSTL
万方数据
